Pharmacokinetics and in vivo specificity of [LLC]dl‐threo‐methylphenidate for the presynaptic dopaminergic neuron
- 12 October 1994
- Vol. 18 (2) , 152-160
- https://doi.org/10.1002/syn.890180207
Abstract
dl‐threo‐Methylphenidate (Ritalin) was labeled with carbon‐11 (t1/2:20.4 minutes) in order to measure its pharmacokinetics, to evaluate it as a radiotracer for the presynaptic dopaminergic neuron, and to examine its sensitivity to the loss of dopaminergic neurons. Positron emission tomographic (PET) studies were carried out in the baboon to determine specificity for the presynaptic dopaminergic neuron and in humans to assess sensitivity to neuronal loss. Studies with [llC]dl‐threo‐methylphenidate ([llC]MP) in baboon demonstrated high regional uptake in the striatum. Peak uptake (0.04%/cc) occurred at 5‐15 minutes post‐injection. The half‐time for clearance from peak uptake for [11C]MP was 60 minutes and the ratio between the radioactivity in the striatum and that in the cerebellum (ST/CB) ranged from 2.2 to 2.6 at 40 minutes. Repeated measures in the same baboon showed ≤8% variability in the ST/CB ratio. Pretreatment with unlabeled methylphenidate (0.5 mg/kg) or GBR12909 (1.5 mg/kg) 30 minutes prior to [11C]MP injection markedly reduced the striatal but not the cerebellar uptake of [11C]MP, demonstrating the saturable and specific binding of [11C]MP to a site on the dopamine transporter in the brain. In both cases, the ratio of striatum to cerebellum (ST/CB) after pretreatment was reduced by about 43% The ratios of distribution volumes at the steady‐state for the striatum to cerebellum (ST/CB) for these two separate studies in the same baboon were reduced by 37 and 38%, respectively. In contrast, pretreatment with tomoxetine (1.5 mg/kg) or citalopram (2.0 mg/kg), inhibitors of the norepinephrine and serotonin transporter, respectively, did not produce a significant change in the kinetics of [11C]MP and the ST/CB after pretreatment was similar to that for control. In one patient with Parkinson's disease, the striatum to cerebellum ratio of [11C]MP was markedly lower than that of an elderly normal subject. These results demonstrate the saturable [11C]MP binding to the dopamine transporter in the baboon brain and that [11C]MP is sensitive to dopamine neuron degeneration in Parkinson's disease. © 1994 Wiley‐Liss, Inc This article is a US Government work and, as such, is in the public domain in the United States of America .Keywords
This publication has 36 references indexed in Scilit:
- Monoamine neurons in aging and Alzheimer's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primatesSynapse, 1993
- Regional distribution and kinetics of haloperidol binding in human brain: A pet study with [18F]haloperidolSynapse, 1992
- In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine‐123 labeled RTI‐55Synapse, 1992
- Possible mechanisms underlying the special vulnerability of dopaminergic neuronsActa Neurologica Scandinavica, 1991
- Evidence that Dogs Do Not Model Enantioselective Pharmacokinetics of dl-Methylphenidate in HumansJournal of Pharmaceutical Sciences, 1991
- A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1990
- Synthesis of racemic (+) and (−) N-[methyl-11C]nomifensine, a ligand for evaluation of monoamine re-uptake sites by use of positron emission tomographyInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1989
- [3H]GBR-12935 Binding to the Dopamine Transporter Is Decreased in the Caudate Nucleus in Parkinson's DiseaseJournal of Neurochemistry, 1987
- A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDRENJournal of Child Psychology and Psychiatry, 1977